{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:15:28Z","timestamp":1791357328821,"version":"4.3.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jaci.2024.09.031","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T23:27:53Z","timestamp":1732318073000},"page":"62-69.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology"],"prefix":"10.1016","volume":"155","author":[{"given":"Aikaterini","family":"Anagnostou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Andrew","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Chinthrajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"Dribin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Fleischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Nowak-Wegrzyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Rachid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus S.","family":"Shaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Shreffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Sicherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Vickery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamini V.","family":"Virkud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2365-9372","authenticated-orcid":false,"given":"Matthew","family":"Greenhawt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2024.09.031_bib1","unstructured":"US Food & Drug Adminstration. FDA approves first medication to help reduce Allergic reactions to multiple foods after accidental exposure. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-medication-help-reduce-allergic-reactions-multiple-foods-after-accidental. Accessed May 20, 2024."},{"key":"10.1016\/j.jaci.2024.09.031_bib3","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jaci.2024.03.019","article-title":"A practical guide for implementing omalizumab therapy for food allergy","volume":"53","author":"Casale","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.09.031_bib4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.anai.2024.03.006","article-title":"Who are the potential patients for omalizumab for food allergy?","volume":"132","author":"Sampson","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2024.09.031_bib5","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1111\/all.16145","article-title":"The use of omalizumab in food allergy","volume":"l79","author":"Alkotob","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.09.031_bib6","first-page":"67","article-title":"an anti-IgE antibody for asthma","volume":"45","year":"2003","journal-title":"In: The Medical Letter on\u00a0Drugs and Therapeutics. New Rochelle, NY: The Medical Letter, Inc"},{"key":"10.1016\/j.jaci.2024.09.031_bib7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0895-4356(96)00377-0","article-title":"Clinical impact versus factor analysis for quality of life questionnaire construction","volume":"50","author":"Juniper","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaci.2024.09.031_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JHL.S352500","article-title":"An Adaptation of the RAND\/UCLA modified delphi panel method in the time of COVID-19","volume":"14","author":"Broder","year":"2022","journal-title":"J Healthc Leadersh"},{"key":"10.1016\/j.jaci.2024.09.031_bib9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.09.031_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacig.2022.05.006","article-title":"Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)","volume":"1","author":"Wood","year":"2022","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaci.2024.09.031_bib11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaci.2020.08.039","article-title":"Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients","volume":"147","author":"Azzano","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.09.031_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/pai.14057","article-title":"Omalizumab in severe asthma and food allergies with IgE levels >1500 kU\/L: two-year evaluation","volume":"34","author":"Dinardo","year":"2023","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2024.09.031_bib13","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3390\/biomedicines11051378","article-title":"The very low IgE producer: allergology, genetics, immunodeficiencies, and oncology","volume":"11","author":"Matricardi","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jaci.2024.09.031_bib14","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jaci.2020.07.031","article-title":"Peanut allergy diagnosis: a 2020 practice parameter update, systematic review, and GRADE analysis","volume":"146","author":"Greenhawt","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.09.031_bib15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jaip.2018.12.008","article-title":"Harmonization of terminology for tolerated and reactive dose in food allergy immunotherapy","volume":"7","author":"Casale","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.09.031_bib16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jaci.2009.05.027","article-title":"Summary of the 2008 National Institute of Allergy and Infectious Diseases-US Food and Drug Administration Workshop on Food Allergy Clinical Trial Design","volume":"124","author":"Plaut","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.09.031_bib17","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.anai.2018.06.018","article-title":"Understanding caregiver goals, benefits, and acceptable risks of peanut allergy therapies","volume":"121","author":"Greenhawt","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2024.09.031_bib18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.anai.2020.05.031","article-title":"Shared decision-making in the care of a patient with food allergy","volume":"125","author":"Greenhawt","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2024.09.031_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2500\/jfa.2023.5.230001","article-title":"Shared decision-making, communicating risk, and food allergy in 2023","volume":"5","author":"Shaker","year":"2023","journal-title":"J Food Allergy"},{"key":"10.1016\/j.jaci.2024.09.031_bib20","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jaip.2023.11.032","article-title":"The role of biologics in the treatment of food allergy","volume":"12","author":"Sindher","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.09.031_bib21","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jaip.2022.11.036","article-title":"Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis","volume":"11","author":"Zuberbier","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.09.031_bib22","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jaci.2012.05.039","article-title":"Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy","volume":"130","author":"Savage","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.09.031_bib23","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/pai.12259","article-title":"Possible recurrence of symptoms after discontinuation of omalizumab in anti-IgE-assisted desensitization to egg","volume":"25","author":"Lafuente","year":"2014","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2024.09.031_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1710-1492-10-7","article-title":"Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab","volume":"10","author":"Begin","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaci.2024.09.031_bib25","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/pai.12567","article-title":"Anti-IgE-assisted desensitization to egg and cow's milk in patients refractory to conventional oral immunotherapy","volume":"27","author":"Martorell-Calatayud","year":"2016","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2024.09.031_bib26","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy","volume":"137","author":"Wood","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.09.031_bib27","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jaci.2013.09.046","article-title":"A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients","volume":"132","author":"Schneider","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.09.031_bib28","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cea.12862","article-title":"Individually dosed omalizumab: an effective treatment for severe peanut allergy","volume":"47","author":"Brandstrom","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2024.09.031_bib29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13223-017-0223-8","article-title":"Observational long-term follow-up study of rapid food oral immunotherapy with omalizumab","volume":"13","author":"Andorf","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaci.2024.09.031_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16730-6","article-title":"Oral immunotherapy combined with omalizumab for high-risk cow's milk allergy: a randomized controlled trial","volume":"7","author":"Takahashi","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2024.09.031_bib31","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jaci.2016.08.010","article-title":"Omalizumab facilitates rapid oral desensitization for peanut allergy","volume":"139","author":"MacGinnitie","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.09.031_bib32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jaci.2024.09.031_bib33","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/pai.13517","article-title":"Oral immunotherapy in severe cow's milk allergic patients treated with omalizumab: real life survey from a Spanish registry","volume":"32","author":"Ibanez-Sandin","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2024.09.031_bib34","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1111\/all.15217","article-title":"Phase 2, randomized multi oral immunotherapy with omalizumab 'real life' study","volume":"77","author":"Sindher","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.09.031_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15586\/aei.v50i3.537","article-title":"Long-term outcome of omalizumab-assisted desensitisation to cow's milk and eggs in patients refractory to conventional oral immunotherapy: real-life study","volume":"50","author":"Ayats-Vidal","year":"2022","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.jaci.2024.09.031_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3121\/cmr.2022.1730","article-title":"The effectiveness of oral immunotherapy in patients with sesame anaphylaxis using omalizumab","volume":"20","author":"Salari","year":"2022","journal-title":"Clin Med Res"},{"key":"10.1016\/j.jaci.2024.09.031_bib37","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jaip.2019.01.023","article-title":"Impact of omalizumab on food allergy in patients treated for asthma: a real-life study","volume":"7","author":"Fiocchi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.09.031_bib38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.15586\/aei.v49i2.36","article-title":"Real life study of the use of omalizumab for pediatric patients with multiple food allergies","volume":"49","author":"Crespo","year":"2021","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.jaci.2024.09.031_bib39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.anai.2023.03.030","article-title":"Anti-immunoglobulin E for food allergy","volume":"131","author":"Dantzer","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2024.09.031_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100690","article-title":"The rationale for development of ligelizumab in food allergy","volume":"15","author":"Wood","year":"2022","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaci.2024.09.031_bib41","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.jaip.2019.11.004","article-title":"Optimizing value in the evaluation of chronic spontaneous urticaria: a cost-effectiveness analysis","volume":"8","author":"Shaker","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.09.031_bib42","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.jaip.2024.06.023","article-title":"The cost effectiveness of treatment of food allergy","volume":"12","author":"Shaker","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.09.031_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jval.2015.09.2938","article-title":"The \"efficacy-effectiveness gap\": historical background and current conceptualization","volume":"19","author":"Nordon","year":"2016","journal-title":"Value Health"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924011771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924011771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T19:50:15Z","timestamp":1750708215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674924011771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0091674924011771"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2024.09.031","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2024.09.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}